Biotech Values

[ggwpq]

Mufaso, great point about "more Semaglutide is delivered orally for Rybelsus than SubQ". Following is the trial design for Lily's oral:

https://dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15150, you can see some good separation in the 4-week curve.

I believe all 4-week oral GLP-1 phase 1 trials (LLY, PFE, GPCR, etc.) show efficacy greater than 3%, which bodes well for VK 2735 oral. Hopefully, with the introduction of GIP, VK2735 will do better in SAEs compared with other GLP-1-only oral trials.